Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer
Researchers from University of London, Imperial College publish new studies and findings in the area of cancer
September 18th, 2008
According to a study from London, the United Kingdom, "This study characterises two recently developed anticancer agents in vitro and in vivo, 2-methoxyoestra-1,3,5(10), 16-tetraene-3-carboxamide (IRC-110160) and STX140. Hormone-dependent (MCF-7), hormone-independent (MDA-MB-231) and P-glycoprotein overexpressing (MCF-7(DOX)) cells were used for proliferation experiments." "For the tumour efficacy studies, female nude mice were inoculated with MDA-MB-231 cells. IRC-110160 is a potent inhibitor of both MCF-7 and MDA-MB-231 cell proliferation. Furthermore, the potency of IRC-110160 was unaffected by the over-expression of the P-glycoprotein drug efflux pump. IRC-110160...
Source: Women's Health Weekly (2008-09-18)
|
